Education
About Us
Working with TipRanks
Follow Us
Wave Life Sciences (WVE)
NASDAQ:WVE
WVE Analyst Ratings
Strong Buy
12 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
WVE Stock 12 Month Forecast
Average Price Target
$17.50
▲(97.96% Upside)
| Highest Price Target$24.00 | Average Price Target$17.50 | Lowest Price Target$8.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$8.5
Hold
-3.85%
Downside
Reiterated
08/01/25
The overall stock score of 55 reflects the company's strong technical momentum and promising clinical advancements weighed against significant financial challenges. While the company's clinical progress and strong cash position are positives, the financial instability and poor valuation metrics detract from the stock's attractiveness.
Canaccord Genuity
$19
Buy
114.93%
Upside
Initiated
08/04/25
Mizuho Securities
$22
Buy
148.87%
Upside
Reiterated
08/04/25
Truist Financial
―
Buy
―
Reiterated
07/31/25
H.C. Wainwright
$22
Buy
148.87%
Upside
Reiterated
07/31/25
Wells Fargo
$24→$21
Buy
137.56%
Upside
Reiterated
07/31/25
Oppenheimer
$24
Buy
171.49%
Upside
Initiated
07/31/25
Leerink Partners
$24
Buy
171.49%
Upside
Reiterated
07/30/25
Wave Life Sciences Poised for Growth: Buy Rating Affirmed Amid Upcoming CatalystsWe think these updates will be very important for WVE, which will begin with 200 mg multi-dose data for WVE-006 in 3Q25, then 400 mg single dose data in Fall 2025, and culminate with WVE-007 data for Cohorts 1 and 2 in 4Q25 and Cohort 3 in 1Q26. The stock's performance has been fairly lackluster in 1H25, which we think has been driven by a perceived lack of catalysts as WVE has been executing on these programs. As such, we encourage investors who have been on the sidelines to tune back in and re-engage with WVE ahead of these readouts. We continue to like WVE as one of our top picks this year based on our view that these data could provide multiple opportunities for significant appreciation in 2H25 and beyond. We are updating our model for quarterly results, leaving our $24 PT unchanged. Reiterate Outperform.
RBC Capital
$9
Hold
1.81%
Upside
Reiterated
07/30/25
Wedbush
$18
Buy
103.62%
Upside
Reiterated
07/30/25
Citi
$16
Buy
81.00%
Upside
Initiated
07/17/25
Cantor Fitzgerald
$10
Buy
13.12%
Upside
Reiterated
07/11/25
Raymond James
$14
Buy
58.37%
Upside
Initiated
06/10/25
JonesTrading
$20
Buy
126.24%
Upside
Reiterated
05/16/25
We are at ASGCT this week and caught Wave's oral sessions on their siRNA and RNA editing programs.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$8.5
Hold
-3.85%
Downside
Reiterated
08/01/25
The overall stock score of 55 reflects the company's strong technical momentum and promising clinical advancements weighed against significant financial challenges. While the company's clinical progress and strong cash position are positives, the financial instability and poor valuation metrics detract from the stock's attractiveness.
Canaccord Genuity
$19
Buy
114.93%
Upside
Initiated
08/04/25
Mizuho Securities
$22
Buy
148.87%
Upside
Reiterated
08/04/25
Truist Financial
―
Buy
―
Reiterated
07/31/25
H.C. Wainwright
$22
Buy
148.87%
Upside
Reiterated
07/31/25
Wells Fargo
$24→$21
Buy
137.56%
Upside
Reiterated
07/31/25
Oppenheimer
$24
Buy
171.49%
Upside
Initiated
07/31/25
Leerink Partners
$24
Buy
171.49%
Upside
Reiterated
07/30/25
Wave Life Sciences Poised for Growth: Buy Rating Affirmed Amid Upcoming CatalystsWe think these updates will be very important for WVE, which will begin with 200 mg multi-dose data for WVE-006 in 3Q25, then 400 mg single dose data in Fall 2025, and culminate with WVE-007 data for Cohorts 1 and 2 in 4Q25 and Cohort 3 in 1Q26. The stock's performance has been fairly lackluster in 1H25, which we think has been driven by a perceived lack of catalysts as WVE has been executing on these programs. As such, we encourage investors who have been on the sidelines to tune back in and re-engage with WVE ahead of these readouts. We continue to like WVE as one of our top picks this year based on our view that these data could provide multiple opportunities for significant appreciation in 2H25 and beyond. We are updating our model for quarterly results, leaving our $24 PT unchanged. Reiterate Outperform.
RBC Capital
$9
Hold
1.81%
Upside
Reiterated
07/30/25
Wedbush
$18
Buy
103.62%
Upside
Reiterated
07/30/25
Citi
$16
Buy
81.00%
Upside
Initiated
07/17/25
Cantor Fitzgerald
$10
Buy
13.12%
Upside
Reiterated
07/11/25
Raymond James
$14
Buy
58.37%
Upside
Initiated
06/10/25
JonesTrading
$20
Buy
126.24%
Upside
Reiterated
05/16/25
We are at ASGCT this week and caught Wave's oral sessions on their siRNA and RNA editing programs.
Best Analysts Covering Wave Life Sciences
1 Month
xxx
Success Rate
8/15 ratings generated profit
Average Return
+6.69%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +6.69% per trade.
3 Months
xxx
Success Rate
8/15 ratings generated profit
Average Return
+21.51%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +21.51% per trade.
1 Year
Success Rate
12/15 ratings generated profit
Average Return
+32.88%
reiterated a buy rating 7 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +32.88% per trade.
2 Years
xxx
Success Rate
12/15 ratings generated profit
Average Return
+35.53%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +35.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
WVE Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
17
21
15
19
14
Buy
5
5
3
4
3
Hold
8
10
6
8
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
36
24
31
24
Each month's total comprises the sum of three months' worth of ratings.
WVE Financial Forecast
WVE Stock Forecast FAQ
What is WVE’s average 12-month price target, according to analysts?
Based on analyst ratings, Wave Life Sciences’s 12-month average price target is 17.50.
What is WVE’s upside potential, based on the analysts’ average price target?
Wave Life Sciences has 97.96% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is WVE a Buy, Sell or Hold?
Wave Life Sciences has a consensus rating of Strong Buy which is based on 12 buy ratings, 2 hold ratings and 0 sell ratings.
What is Wave Life Sciences’s price target?
The average price target for Wave Life Sciences is 17.50. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $24.00 ,the lowest forecast is $8.50. The average price target represents 97.96% Increase from the current price of $8.84.
The highest analyst price target is $24.00 ,the lowest forecast is $8.50. The average price target represents 97.96% Increase from the current price of $8.84.
What do analysts say about Wave Life Sciences?
Wave Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of WVE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.